Recombinant FVII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A: Update of safety, efficacy and inhibitor development after seven study years

被引：0
|
作者：
Lusher, J
Arkin, S
Abildgaard, CF
Hurst, A
机构：
[1] MT SINAI SCH MED, NEW YORK, NY USA
[2] WAYNE STATE UNIV, DETROIT, MI USA
[3] UNIV CALIF DAVIS, SACRAMENTO, CA 95817 USA
[4] BAYER CORP, BERKELEY, CA USA
来源：
THROMBOSIS AND HAEMOSTASIS | 1997年
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：PD664 / PD664
页数：1
相关论文
共 50 条
  • [31] The use of recombinant factor VIII products in previously treated patients with hemophilia A: Pharmacokinetics, efficacy, safety, and inhibitor development
    Lee, C
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03): : 241 - 246
  • [32] Recombinant factor IX (rFIX) treatment of previously untreated patients (PUPs) with severe or moderately severe hemophilia B.
    Shapiro, A
    Abshire, T
    Kisker, T
    Lee, C
    Pasi, J
    Pollmann, H
    Nguyen, K
    Nissen, S
    BLOOD, 2000, 96 (11) : 264A - 265A
  • [33] Recombinant factor IX (rFIX) in the treatment of previously untreated patients (PUPS) with severe or moderately severe hemophilia B.
    Shapiro, A
    Pasi, KJ
    Abshire, T
    Kisker, CT
    Cohen, A
    Goddard, J
    Courter, S
    BLOOD, 1997, 90 (10) : 684 - 684
  • [34] Safety and efficacy of recombinant factor VIII for the treatment of previously treated patients with hemophilia A in China
    Yang, R.
    Zhao, Y.
    Sun, J.
    Wu, J.
    Wang, X.
    Yu, M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 507 - 507
  • [35] First and second generation recombinant factor VIII concentrates in previously untreated patients: Recovery, safety, efficacy, and inhibitor development
    Lusher, JM
    SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2002, 28 (03): : 273 - 276
  • [36] Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
    Gouw, Samantha C.
    van der Bom, Johanna G.
    van den Berg, H. Marijke
    BLOOD, 2007, 109 (11) : 4648 - 4654
  • [37] Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A
    Gouw, S. C.
    van den Berg, H. M.
    le Cessie, S.
    van der Bom, J. G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2007, 5 (07) : 1383 - 1390
  • [38] Inhibitor development in previously treated patients with hemophilia A after switch to recombinant factor VIII
    Wu, Y.
    Tsay, W.
    Lin, H.
    Chang, C.
    Chen, M.
    Shen, M.
    HAEMOPHILIA, 2008, 14 : 52 - 53
  • [39] The type of products (plasmatic vs recombinant) may exert an influence on FVIII inhibitor incidence in previously untreated severe hemophilia a patients (PUPs).
    Goudemand, J
    Rothschild, C
    Demiguel, V
    Lambert, T
    Calvez, T
    BLOOD, 2003, 102 (11) : 798A - 798A
  • [40] Pattern of bleeding episodes in young hemophilia A patients: A natural history of recombinant factor VIII (rFVIII) treatment of previously untreated patients (PUPs).
    Arkin, S
    Lusher, J
    Abildgaard, C
    Bogdanoff, D
    Hurst, D
    BLOOD, 1995, 86 (10) : 3444 - 3444
12345